Codexis CSO discloses stock, RSUs and options in insider filing
Rhea-AI Filing Summary
Codexis, Inc. (CDXS) chief scientific officer reports equity holdings in a beneficial ownership statement dated 11/07/2025. The officer directly owns 143,460 shares of Codexis common stock, including 53,266 restricted stock units that each convert into one share upon vesting. In addition, the officer holds multiple stock options covering shares of common stock with exercise prices ranging from $3.05 to $26.16 and expirations between 2030 and 2035. Some options are already fully vested and exercisable, while others vest over time based on specified schedules tied to dates from 2021 through 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Includes 53,266 Restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit. Option vests with respect to 25% of the shares subject thereto on May 1, 2021, with 1/36th of the shares vesting monthly thereafter. The option is fully vested and exercisable. Option vests with respect to 25% of the shares subject thereto on February 16, 2022, with 1/36th of the shares vesting monthly thereafter. Option vests with respect to 25% of the shares subject thereto on February 7, 2023, with 1/36th of the shares vesting monthly thereafter. Option vests with respect to 25% of the shares subject thereto on February 21, 2024, with 1/36th of the shares vesting monthly thereafter. Option vests with respect to 1/3 of the shares subject thereto on January 1, 2025, with 1/24th of the shares vesting monthly thereafter. Option vests with respect to 25% of the shares subject thereto on February 5, 2026, with 1/36th of the shares vesting monthly thereafter.
FAQ
What does this Codexis (CDXS) insider ownership filing report?
The filing reports the Codexis chief scientific officer’s beneficial ownership of common stock and stock options as of an event dated 11/07/2025, including both directly owned shares and equity awards subject to vesting.
How many restricted stock units does the Codexis officer hold?
The filing states that the total shares include 53,266 restricted stock units, each of which entitles the officer to receive one share of common stock upon vesting.
What stock options are reported for the Codexis (CDXS) officer?
The officer holds several stock options to buy Codexis common stock, with individual awards covering between 8,800 and 209,400 shares and exercise prices from $3.05 to $26.16, expiring between 05/05/2030 and 02/05/2035.
Are any of the Codexis stock options already vested and exercisable?
Yes. One option grant is explicitly described as fully vested and exercisable, while other grants vest over time under specified schedules based on dates such as May 1, 2021 and February 5, 2026.
What role does the reporting person hold at Codexis (CDXS)?
The reporting person is identified as an officer of Codexis, serving in the role of chief scientific officer (CSO).
Is this Codexis (CDXS) insider filing made by a single reporting person?
Yes. The form indicates it is filed by one reporting person, not by a group or multiple insiders.